Loading…
CIK 0001637359 • 7 13F filings • May 15, 2025 – Aug 14, 2026
Import this data to Google Sheets with:
=jivedata("omega-fund-management-llc","13f")Uses this filer's slug. Install the Jive Data add-on first; the second argument is "13f".
Past 5 quarters
| % of Portfolio | |||||
|---|---|---|---|---|---|
| Alumis Inc. | Common Stock | $6.4M | 2.2% | 653,223 SH | New |
| Beta Bionics Inc. | Common Stock | $40.1M | 14.0% | 1,316,183 SH | New |
| Bicara Therapeutics Inc. | Common Stock | $37.1M | 12.9% | 2,204,650 SH | New |
| BridgeBio Oncology Therapeutics Inc. | Common Stock | $41.2M | 14.4% | 3,289,661 SH | New |
| enGene Holdings Inc. | Common Stock | $7.9M | 2.8% | 876,357 SH | New |
| ImageneBio, Inc. | Common Stock | $3.1M | 1.1% | 455,361 SH | New |
| Kestra Med Technologies Ltd | Common Stock | $36.4M | 12.7% | 1,373,591 SH | New |
| Nuvation Bio | Common Stock Class A | $72.4M | 25.3% | 8,081,089 SH | New |
| Replimune Group | Common Stock | $2.4M | 0.8% | 248,672 SH | New |
| Sana Biotechnology, Inc. | Common Stock | $3.4M | 1.2% | 843,750 SH | New |
| Upstream Bio Inc. | Common Stock | $36.0M | 12.6%Prev: 100.0% | 1,326,293 SH | Increased-710,000 SH |
| 13F-HR |
| 0001193125-25-281790 |
| $222.4M |
| View |
| Aug 14, 2026 | Q2 2026 | 13F-HR | 0001193125-26-350681 | $185.7M | View |
| Aug 14, 2025 | Q2 2025 | 13F-HR | 0000950123-25-008066 | $154.4M | View |
| May 15, 2026 | Q1 2026 | 13F-HR | 0001193125-26-225480 | $163.1M | View |
| May 15, 2025 | Q1 2025 | 13F-HR | 0000950123-25-005509 | $169.5M | View |